Martinelli I, Mannucci P M, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni E M
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Epidemiology Unit, IRCCS Maggiore Hospital and University of Milan, Milan, Italy.
Blood. 1998 Oct 1;92(7):2353-8.
Deficiency of the naturally occurring anticoagulant proteins, such as antithrombin, protein C and protein S, and activated protein C resistance due to the factor V Leiden gene mutation is associated with inherited thrombophilia. So far, no direct comparison of the thrombotic risk associated with these genetic defects is available. In this study, we wish to compare the lifetime probability of developing thrombosis, the type of thrombotic symptoms, and the role of circumstantial triggering factors in 723 first- and second-degree relatives of 150 index patients with different thrombophilic defects. We found higher risks for thrombosis for subjects with antithrombin (risk ratio 8.1, 95% confidence interval [CI], 3.4 to 19.6), protein C (7.3, 95% CI, 2.9 to 18.4) or protein S deficiency (8.5, 95% CI, 3. 5 to 20.8), and factor V Leiden (2.2, 95% CI, 1.1 to 4.7) than for individuals with normal coagulation. The risk of thrombosis for subjects with factor V Leiden was lower than that for those with all three other coagulation defects (0.3, 95% CI, 0.1 to 1.6), even when arterial and superficial vein thromboses were excluded and the analysis was restricted to deep vein thrombosis (0.3, 95% CI, 0.2 to 0.5). No association between coagulation defects and arterial thrombosis was found. The most frequent venous thrombotic manifestation was deep vein thrombosis with or without pulmonary embolism (90% in antithrombin, 88% in protein C, 100% in protein S deficiency, and 57% in factor V Leiden), but a relatively mild manifestation such as superficial vein thrombosis was common in factor V Leiden (43%). There was a predisposing factor at the time of venous thromboembolism in approximately 50% of cases for each of the four defects. In conclusion, factor V Leiden is associated with a relatively small risk of thrombosis, lower than that for antithrombin, protein C, or protein S deficiency. In addition, individuals with factor V Leiden develop less severe thrombotic manifestations, such as superficial vein thrombosis.
天然存在的抗凝蛋白缺乏,如抗凝血酶、蛋白C和蛋白S,以及因因子V莱顿基因突变导致的活化蛋白C抵抗,与遗传性易栓症相关。到目前为止,尚无关于这些遗传缺陷相关血栓形成风险的直接比较。在本研究中,我们希望比较150例患有不同易栓症缺陷的索引患者的723名一级和二级亲属发生血栓形成的终生概率、血栓形成症状的类型以及环境触发因素的作用。我们发现,抗凝血酶缺乏(风险比8.1,95%置信区间[CI],3.4至19.6)、蛋白C缺乏(7.3,95%CI,2.9至18.4)或蛋白S缺乏(8.5,95%CI,3.5至20.8)以及因子V莱顿突变(2.2,95%CI,1.1至4.7)的受试者发生血栓形成的风险高于凝血功能正常的个体。因子V莱顿突变受试者的血栓形成风险低于其他三种凝血缺陷受试者(0.3,95%CI,0.1至1.6),即使排除动脉和浅静脉血栓形成并将分析限于深静脉血栓形成时也是如此(0.3,95%CI,0.2至0.5)。未发现凝血缺陷与动脉血栓形成之间存在关联。最常见的静脉血栓形成表现是伴有或不伴有肺栓塞的深静脉血栓形成(抗凝血酶缺乏者中为90%,蛋白C缺乏者中为88%,蛋白S缺乏者中为100%,因子V莱顿突变者中为57%),但因子V莱顿突变者中相对较轻的表现如浅静脉血栓形成较为常见(43%)。在四种缺陷中的每一种缺陷导致静脉血栓栓塞时,约50%的病例存在诱发因素。总之,因子V莱顿突变与相对较小的血栓形成风险相关,低于抗凝血酶、蛋白C或蛋白S缺乏者。此外,因子V莱顿突变个体发生的血栓形成表现较轻,如浅静脉血栓形成。